Dysregulated translation drives key hallmarks of cancer and is controlled by Phase 2 candidate eFT508 binding to the MNK protein, exploiting stereoelectronic interactions, critical to the compound’s selectivity and potency. Read more »
An antibody was modified to activate a specific pathway of the immune system, demonstrating its value in killing tumor cells. The work provides a platform for disentangling different immune-system pathways and could lead to the design of improved immunotherapies. Read more »
A recently awarded National Institutes of Health (NIH) grant will help integrate existing structural biology resources at the ALS to better serve users. The funds will help establish a centralized collaborative mechanism, called ALS-ENABLE, that will guide users through the most appropriate routes for answering their biological questions. Read more »
Type 2 diabetes mellitus (T2DM), characterized by abnormally high blood glucose levels, affects hundreds of millions of people worldwide. In the pursuit to better treat this disease, the human receptor protein GPR40 has been identified by pharmaceutical company Takeda as a potential new drug target.